Ad-MAGEA3

AXP000165.1 · Cancer vaccine

Platform
adenovirus (Ad5, MAGE-A3)
Targets
MAGEA3
Originator
Turnstone Biologics
Sponsor
Turnstone Biologics

Names

NameTypeSource
Ad-MAGEA3preferred name, codecurator, ncit
AdMA3codencit
Adenovirus/MAGE-A3 ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating adenoviral vector encoding MAGE-A3
Transgenes
MAGEA3
Route
intramuscular
Source
evidence

Cross-references

NCI Thesaurus
C119614

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03773744MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnPhase 12020-02-152020-10-300Metastatic Melanoma; Squamous Cell Skin Carcinoma
NCT02879760Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedPhase 1/22017-03-082020-02-1516Non-Small Cell Lung Cancer
NCT02285816MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid TumoursActive not recruitingPhase 1/22015-01-222019-09-1956Advanced/Metastatic Solid Tumours

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40389376Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.Journal for immunotherapy of cancer2025cited by trial NCT02285816
PMID 33608375In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.Journal for immunotherapy of cancer2021cited by trial NCT02285816
PMID 30546947Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.Oncoimmunology2019cited by trial NCT02285816

Notes

Adenovirus type 5 expressing MAGE-A3, used as the priming dose before the oncolytic MG1-MAGEA3 Maraba rhabdovirus boost (NCIt C118973, a separate oncolytic program). Phase 1/2 in MAGE-A3-positive solid tumours and NSCLC. The NCIt record 'MAGE-A3-expressing Adenovirus Type 5 Vaccine' (synonyms Adenovirus/MAGE-A3, AdMA3) does not name Turnstone, so the identification rests on the trial literature and should be checked.

How to cite

Ad-MAGEA3 (AXP000165.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000165.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.